Group 1 - The pharmaceutical and biotechnology index increased by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index rose by 6.8%, surpassing the Hang Seng China Enterprises Index by 5.4 percentage points [4] Group 2 - There is a notable increase in flu-like cases since the beginning of autumn 2025, indicating a potentially severe flu season this year. In the 45th week of 2025, 21,412 flu-like case samples were tested, with positive samples primarily being A(H3N2) [5] - The change in circulating strains compared to previous years may increase the risk of breaching herd immunity, although predicting respiratory virus outbreaks remains uncertain [5] Group 3 - Future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing the clinical needs of patients, as both domestic healthcare policies and global expansion strategies increasingly emphasize clinical value [6] - Risks include unexpected cost control policies, research and development failures, insufficient policy support, and slower-than-expected promotion of commercial health insurance [6]
【医药】流感样病例占比持续走高，关注流感疫苗、呼吸道病毒检测、感冒药等板块——行业跨市场周报（251117）（王明瑞/黎一江）
光大证券研究·2025-11-17 23:03